HomeCompareZIOP vs GIS

ZIOP vs GIS: Dividend Comparison 2026

ZIOP yields 231.03% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZIOP wins by $281.92M in total portfolio value
10 years
ZIOP
ZIOP
● Live price
231.03%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281.99M
Annual income
$152,307,756.02
Full ZIOP calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — ZIOP vs GIS

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZIOPGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZIOP + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZIOP pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP
Annual income on $10K today (after 15% tax)
$19,637.29/yr
After 10yr DRIP, annual income (after tax)
$129,461,592.62/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, ZIOP beats the other by $129,447,813.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + GIS for your $10,000?

ZIOP: 50%GIS: 50%
100% GIS50/50100% ZIOP
Portfolio after 10yr
$141.04M
Annual income
$76,161,983.64/yr
Blended yield
54.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

ZIOP
No analyst data
Altman Z
-287.0
Piotroski
3/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys
0
GIS buys
0
No recent congressional trades found for ZIOP or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZIOPGIS
Forward yield231.03%6.53%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$281.99M$78.8K
Annual income after 10y$152,307,756.02$16,211.26
Total dividends collected$267.75M$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ZIOP vs GIS ($10,000, DRIP)

YearZIOP PortfolioZIOP Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$33,803$23,102.69$11,502$801.73+$22.3KZIOP
2$109,153$72,984.41$13,365$1,058.29+$95.8KZIOP
3$337,052$220,258.08$15,712$1,411.34+$321.3KZIOP
4$996,281$635,635.69$18,716$1,904.17+$977.6KZIOP
5$2,821,960$1,755,939.31$22,629$2,603.16+$2.80MZIOP
6$7,667,803$4,648,304.92$27,826$3,612.21+$7.64MZIOP
7$20,008,593$11,804,044.41$34,871$5,097.54+$19.97MZIOP
8$50,195,948$28,786,753.46$44,643$7,331.52+$50.15MZIOP
9$121,203,020$67,493,355.30$58,541$10,772.15+$121.14MZIOP
10$281,994,987$152,307,756.02$78,850$16,211.26+$281.92MZIOP

ZIOP vs GIS: Complete Analysis 2026

ZIOPStock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this ZIOP vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHDZIOP vs JEPIZIOP vs OZIOP vs KOZIOP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.